Navigation Links
Lotus Pharmaceuticals, Inc. Announces 2010 Growth Strategy
Date:10/19/2009

BEIJING, Oct. 19 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company") a growing developer and producer of prescriptions drugs and licensed national seller of pharmaceutical products in the People's Republic of China, today announced its 2010 growth strategy.

    Lotus's priorities for the balance of 2009 are
    1) deciding what the Company needs to do for its most valuable customers
       and continuing on its efforts, and
    2) identifying new product and market demand, and
    3) preparing for the construction of a new office building on the ground
       of its existing plant so that operational efficiency could be achieved
       by moving the separate units of sales, production and R&D bases into
       one single location.  This has been made possible because the
       government approved the zoning right of Lotus's property in Beijing to
       upgrade to industrial use in June of 2009.  Lotus is permitted to build
       gross floor areas of 20,353 square meters in four-nine floors above the
       ground and one floor underground.

Dr. Zhong Yi Liu, Chairman and CEO of Lotus commented, "Based on the past two years of business expansion, we currently believe that we will achieve our financial goals for the year 2009 and grow steady in the year of 2010." The Company's growth plan for the next year, includes, but is not limited to the following areas:

Expand Sales Network. Lotus currently plans to add 15-20 more distributors by the end of 2010 to its nation-wide sales channels. Lotus attends substantially every major drug expos in China. Lotus's sales representatives are experienced with medical education backgrounds, and are located in ten regional sales centers providing sales and post-sales services to its customers. Regional distributors come into contact with Lotus through words of mouth and public information.


'/>"/>

SOURCE Lotus Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Lotus Pharmaceuticals Announces Second Quarter 2008 Results
2. Lotus Scarless Hair Transplantation (International) Medical Chain Institute Opens New Center on Beijings Prestigious ChangAn Avenue
3. Lotus Pharmaceuticals, Inc. Announces Patent Pending Gliclazide-Controlled Release Tablets
4. Lotus Pharmaceuticals, Inc. Reports Second Quarter 2009 Financial Results
5. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
6. Prestwick Pharmaceuticals, Inc. Continues to Build Management Team With Appointment of Martin Stogniew, Ph.D. as Executive Vice President, Chief Technology Officer
7. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
8. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
9. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
10. NPS Pharmaceuticals, Inc. Announces an Increase in Tender Offer Price for Its 3.0% Convertible Notes Due 2008 and Extends Expiration Date Until October 17, 2007
11. Alseres Pharmaceuticals, Inc. to Present at Bio Investor Forum 2007 Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... September 18, 2014 ... http://www.researchandmarkets.com/research/czvg3s/biocompatible ) has announced the addition ... Global Strategic Business Report" report ... ,This report analyzes the worldwide markets ... by the following Product Segments: Polymeric ...
(Date:9/18/2014)... , Sept. 18, 2014 Research and ... "Global and Chinese Stem Cell Industry Report, 2014-2017" ... are undifferentiated biological cells that can differentiate into specialized ... stem cells. Stem cell therapy can be applied to ... system disease), nervous system diseases, damage or lesion of ...
(Date:9/18/2014)... Sept. 18, 2014 Research and Markets ... Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market ... their offering. The global companion diagnostics ... 22.7% from 2014 to 2019. Factors such as rising ... of companion diagnostics by the pharmaceutical industry, support from ...
(Date:9/18/2014)...  MEI Pharma, Inc. (Nasdaq: MEIP ), an ... for cancer, announced today that Daniel P. Gold , ... NewsMakers in the Biotech Industry conference on Friday, ... Millennium Broadway Hotel & Conference Center in New ... be accessed at www.meipharma.com . A replay will be ...
Breaking Biology Technology:Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3Global and Chinese Stem Cell Industry Report, 2014-2017 2Global and Chinese Stem Cell Industry Report, 2014-2017 3Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 3MEI Pharma To Present At BioCentury's NewsMakers Conference 2MEI Pharma To Present At BioCentury's NewsMakers Conference 3
... half of Americans living with colorectal cancer will ... course of their disease. Radiofrequency ablation, a minimally ... tumor causing cancer cell death with minimal associated ... prolongation of their life by nearly three years, ...
... a biodefense company developing medical countermeasures against biological and chemical threats, announced today that its financial results for the year ended 2009 will be released on Tuesday, March 23, 2010 ... , ... ... ...
... , March 16, 2010 Elbit Imaging,(NASDAQ: EMITF ) ("Elbit Imaging" "Company") announced today that its,wholly-owned subsidiary, Elbit Medical Ltd., ... the Tel Aviv,Stock Exchange. , ... , ... ...
Cached Biology Technology:Living longer: Colon cancer patients gain time with radiofrequency ablation treatment 2Living longer: Colon cancer patients gain time with radiofrequency ablation treatment 3PharmAthene to Host Year-End 2009 Earnings Conference Call and Webcast on Tuesday, March 23, 2010 2PharmAthene to Host Year-End 2009 Earnings Conference Call and Webcast on Tuesday, March 23, 2010 3Elbit Imaging Announces Filing of Draft Prospectus for its Subsidiary Elbit Medical Ltd. for Float on Tel Aviv Stock Exchange 2Elbit Imaging Announces Filing of Draft Prospectus for its Subsidiary Elbit Medical Ltd. for Float on Tel Aviv Stock Exchange 3Elbit Imaging Announces Filing of Draft Prospectus for its Subsidiary Elbit Medical Ltd. for Float on Tel Aviv Stock Exchange 4Elbit Imaging Announces Filing of Draft Prospectus for its Subsidiary Elbit Medical Ltd. for Float on Tel Aviv Stock Exchange 5Elbit Imaging Announces Filing of Draft Prospectus for its Subsidiary Elbit Medical Ltd. for Float on Tel Aviv Stock Exchange 6
(Date:9/18/2014)... ever starts a "frequent flyers" program, fruit flies surely ... laboratory has hosted increasing numbers of fruit fly research ... station in April, and another is scheduled launch to ... to launch in December. , Fruit flies are biomedical ... in space. Model organisms can reveal the basis for ...
(Date:9/18/2014)... have built the first smartphone app that automatically ... trends. In other words, your smartphone knows your ... -- and how that affects you. , The ... and loneliness to their academic performance, also may ... example, to monitor mental health, trigger intervention and ...
(Date:9/18/2014)... tropical rabbitfish which have devastated algal forests in the ... entire Mediterranean basin if their distribution continues to expand ... study, by an international team of researchers led by ... Tomas of the Mediterranean Institute for Advanced Studies in ... ., Members of the team surveyed more than 1000 ...
Breaking Biology News(10 mins):Buzzing with activity: Fruit flies orbit Earth for science 2Buzzing with activity: Fruit flies orbit Earth for science 3Buzzing with activity: Fruit flies orbit Earth for science 4New Dartmouth smartphone app reveals users' mental health, performance, behavior 2New Dartmouth smartphone app reveals users' mental health, performance, behavior 3New Dartmouth smartphone app reveals users' mental health, performance, behavior 4Tropical fish a threat to Mediterranean Sea ecosystems 2
... metal scaffolds inserted into blood vessels, to better deliver ... the risk of inflammation that often negates initial benefits. ... an extremely thin layer to bare metal surfaces, may ... make use of metallic implants. , Cardiologists frequently treat ...
... history's worst infectious diseases, but there are many more diseases ... society needs to confront to unlock the future promise of ... focus of a new report by the American Academy of ... been profound. Many diseases that formerly raged unchecked are ...
... flow of carbon through soil is ten times greater than the ... but until now how this happens was at best poorly understood. ... carbon. Now researchers at the University of Warwick have been able ... class of insects to expose the key underground carbon traffic system ...
Cached Biology News:Bare metal stents deliver gene therapy to heart vessels with less inflammation in animal studies 2Report focuses on challenges to unlocking future promise of vaccines 2Bugs expose underground carbon traffic system 10 times more important than fossil fuel burning 2
OmniSlide thermal Cycler for slide applications. 20 slide capacity. Humidity Chamber. Slide Rack can be transferred directly to Wash Module to avoid handling individual slides....
HyPro 100, includes 5 x HyPro20 and HyPro Cabinet. 100 slide capacity. Active vibration system, slide rack and humidity chamber. Ideal for microarray and in situ hybridization....
HyPro 20 system for slide hybridization. 20 slide capacity. Active vibration system, slide rack and humidity chamber. Ideal for microarray and in situ hybridization....
... are cytopathic effect inhibition assays, also known as ... tissue culture supernatents; serum from PK studies and ... is defined as the quantity of interferon required ... viral infection by 50%. All standards ...
Biology Products: